SI-BONE, Inc. SIBN
Set alert
At close · Nov 2
After hours · Nov 2, 4:57 PM ET
- YTD
- +2.54%
- 1 year
- +36.35%
- Open
- 21.57
- Prev close
- 21.23
- Mkt cap
- 896.74M
- Vol
- 1.37M
- Avg vol
- 579.50K
- EPS
- -0.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 20.19
- High
- 21.83
- Forward P/E
- -67.74
- Beta
- 0.66
- Short ratio
- 8.24
- Inst. own
- 109.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 5, 2024
- 50-d avg
- 19.33
- 200-d avg
- 16.36
- 1y target
- 25.44
5D chart
Signals (108)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 3 days ago |
| RSI: Oversold | Oct 30, 2:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:40 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 12:10 PM | 3 days ago |
| RSI: Oversold | Oct 30, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:35 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:50 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 4 days ago |
Newest 20 of 108.
News
5 hours ago seekingalpha.com
SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript
6 hours ago marketbeat.com
SiBone Q3 Earnings Call Highlights
SiBone NASDAQ: SIBN reported third-quarter 2026 revenue growth of 14.5% as procedure demand accelerated, active physician adoption expanded and profitability improved. The company said it is building…
8 hours ago zacks.com
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.
9 hours ago benzinga.com
SI-BONE Q3 2026 Earnings Call Transcript
SI-BONE (NASDAQ:SIBN) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
-
10 hours ago benzinga.com
SI-BONE Affirms FY2026 Sales Guidance of $231.000M-$233.000M vs $232.024M Est
SI-BONE (NASDAQ:SIBN) affirms FY2026 sales outlook from $231.000 million-$233.000 million to $231.000 million-$233.000 million vs $232.024 million estimate.
-
11 hours ago benzinga.com
SI-BONE Q3 EPS $(0.08) Beats $(0.13) Estimate, Sales $55.704M Beat $55.404M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 33.33 percent. This is a 27.27 percent increase over losses of $(0.11) per…
11 hours ago globenewswire.com
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance
Delivered ~20 % U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $55.7 million,…
4 days ago globenewswire.com
SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026
SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone,…
2 weeks ago globenewswire.com
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone,…
-
2 weeks ago benzinga.com
Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $25
Truist Securities analyst Richard Newitter maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $23 to $25.
3 weeks ago gurufocus.com
Is SI-BONE Inc (SIBN) Overvalued After 3.8% Rally? GF Value Says Overvalued
On October 12, 2026, SI-BONE Inc (SIBN) shares rose 3.8% to a current price of $20.10. This movement comes amid a 52-week range that saw a high of $21.89 and a
4 weeks ago defenseworld.net
Analyzing SiBone (NASDAQ:SIBN) & Integer (NYSE:ITGR)
Integer (NYSE: ITGR - Get Free Report) and SiBone (NASDAQ: SIBN - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the…
-
1 month ago benzinga.com
SI-BONE Receives FDA Clearance For Its iFuse Granite Onyx System
SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced U.S. Food and Drug Administration…
1 month ago globenewswire.com
SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis
FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density…
1 month ago seekingalpha.com
SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's after-market session. The market value of their outstanding shares is at $1.1 million. Corbus Pharmaceuticals
2 months ago globenewswire.com
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised…
2 months ago zacks.com
Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?
Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
2 months ago zacks.com
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade
The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…
2 months ago zacks.com
Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?
The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
3 months ago defenseworld.net
SiBone Q2 Earnings Call Highlights
SiBone (NASDAQ: SIBN) reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its…
-
3 months ago benzinga.com
Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $23
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $23.
-
3 months ago benzinga.com
TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $20
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $18 to $20.
3 months ago seekingalpha.com
SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
3 months ago zacks.com
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.14 per share a year ago.
3 months ago marketbeat.com
SiBone Q2 Earnings Call Highlights
SiBone NASDAQ: SIBN reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…
-
3 months ago benzinga.com
SI-BONE Raises FY2026 Sales Guidance from $230.000M-$233.000M to $231.000M-$233.000M vs $231.775M Est
SI-BONE (NASDAQ:SIBN) raises FY2026 sales outlook from $230.000 million-$233.000 million to $231.000 million-$233.000 million vs $231.775 million estimate.
-
3 months ago benzinga.com
SI-BONE Q2 EPS $(0.09) Beats $(0.15) Estimate, Sales $56.010M Beat $55.335M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.15) by 40 percent. This is a 35.71 percent increase over losses of $(0.14) per…
3 months ago globenewswire.com
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
Delivered ~15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base
-
3 months ago benzinga.com
UBS Initiates Coverage On SI-BONE with Buy Rating, Announces Price Target of $24
UBS analyst Patrick Wood initiates coverage on SI-BONE (NASDAQ:SIBN) with a Buy rating and announces Price Target of $24.
3 months ago globenewswire.com
SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026
SANTA CLARA, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised…
-
3 months ago benzinga.com
Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $21
Truist Securities analyst Richard Newitter maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $18 to $21.
3 months ago globenewswire.com
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its…
5 months ago globenewswire.com
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SANTA CLARA, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised…
5 months ago zacks.com
Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now
Si-Bone (SIBN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a…
5 months ago zacks.com
Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 71.1% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the…
5 months ago benzinga.com
Zebra Technologies, Vishay Precision Group, Quantum Computing, Aramark And Other Big Stocks Moving Higher On Tuesday
ZBRA, VSTS, AMBQ, VPG, BAK, PACS, LOT, EIKN, DDD, WEN, SIBN post significant gains on better-than-expected financial results and guidance. Peltz may take Wendy's private.
-
5 months ago benzinga.com
TD Cowen Maintains Buy on SI-BONE, Lowers Price Target to $18
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $22 to $18.
-
5 months ago benzinga.com
Truist Securities Reiterates Buy on SI-BONE, Lowers Price Target to $18
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $20 to $18.
5 months ago benzinga.com
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Harmonic Inc (HLIT) rose in pre-market trading after beating earnings expectations & raising guidance. Other gainers include Buzzfeed, MacroGenics, & SI-Bone.
-
5 months ago benzinga.com
SI-BONE Raises FY2026 Sales Guidance from $228.500M-$232.500M to $230.000M-$233.000M vs $230.387M Est
SI-BONE (NASDAQ:SIBN) raises FY2026 sales outlook from $228.500 million-$232.500 million to $230.000 million-$233.000 million vs $230.387 million estimate.
-
5 months ago benzinga.com
SI-BONE Q1 EPS $(0.10) Beats $(0.18) Estimate, Sales $52.588M Beat $51.105M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 44.44 percent. This is a 33.33 percent increase over losses of $(0.15) per…
-
6 months ago benzinga.com
Truist Securities Maintains Buy on SI-BONE, Lowers Price Target to $20
Truist Securities analyst Samuel Brodovsky maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $24 to $20.
-
8 months ago benzinga.com
TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $22
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $22.
-
8 months ago benzinga.com
Truist Securities Reiterates Buy on SI-BONE, Raises Price Target to $24
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $23 to $24.
-
8 months ago benzinga.com
SI-BONE Q4 EPS $(0.04) Beats $(0.12) Estimate, Sales $56.350M Beat $55.397M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.12) by 67.48 percent. This is a 63.64 percent increase over losses of $(0.11) per…
-
8 months ago benzinga.com
Earnings Scheduled For February 23, 2026
Earnings Scheduled For February 23, 2026